Evox Therapeutics Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Employees
  • 108
Employees
  • Latest Deal Type
  • Series C
  • Latest Deal Amount
  • $95.4M
Latest Deal Amount
  • Investors
  • 12

Evox Therapeutics General Information

Description

Developer of exosome-based therapeutics designed to treat various severe diseases with profound implications for human health. The company's therapeutics use nucleic acid and protein delivery technology to harness and engineer the natural trafficking capabilities of extracellular vesicles, enabling healthcare providers to leverage proprietary targeting, manufacturing processes and purification methods.

Contact Information

Website
www.evoxtherapeutics.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • Oxford Science Park, Medawar Centre
  • 2nd Floor East Building, Robert Robinson Avenue
  • Oxford OX4 4HG
  • England, United Kingdom
+44 01865 000000

Evox Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Evox Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Later Stage VC (Series C) 18-Feb-2021 $95.4M 00000 Completed Generating Revenue
3. Grant 22-Mar-2019 00.000 000.00 Completed Generating Revenue
2. Early Stage VC (Series B) 03-Sep-2018 $45.6M $60.2M 000.00 Completed Generating Revenue
1. Seed Round 10-May-2016 $14.6M $14.6M 0000 Completed Clinical Trials - Phase 1
To view Evox Therapeutics’s complete valuation and funding history, request access »

Evox Therapeutics Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
A Preferred 000,000 00.000000 00 0000.0 0000.0 00 0000.0 00.000
Ordinary 000,000 00.000000 00 000.00 000.00 00 000.00 00.000
To view Evox Therapeutics’s complete cap table history, request access »

Evox Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of exosome-based therapeutics designed to treat various severe diseases with profound implications for human h
Biotechnology
Oxford, United Kingdom
108 As of 2021
00000
00000000000 00000

000000 0

, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
0000 000000000
Miramar, FL
00 As of 0000
000000000 -

000000

velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident,
0000 000000000
Seattle, WA
00 As of 0000
000.00
0000000000 0 000.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Evox Therapeutics Competitors (16)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Kimera Labs Corporation Miramar, FL 00 000000000 -
000000 Venture Capital-Backed Seattle, WA 00 000.00 0000000000 0 000.00
000000 Formerly VC-backed Cambridge, MA 000 00000 00000000 00000
000000 00000000000 Venture Capital-Backed Lexington, MA 00 00000 00000000000 00000
00000000 Venture Capital-Backed Seattle, WA 00 0000 000000000 - 0000
You’re viewing 5 of 16 competitors. Get the full list »

Evox Therapeutics Executive Team (6)

Name Title Board Seat Contact Info
Antonin de Fougerolles Ph.D Chief Executive Officer & Board Member
Per Lundin Ph.D Co-Founder, Chief Operating Officer & Board Member
Samir El-Andaloussi Co-Founder & Head, Protein Engineering
Matthew Wood MD Co-Founder & Board Observer
Paul Carter Chairman
You’re viewing 5 of 6 executive team members. Get the full list »

Evox Therapeutics Board Members (14)

Name Representing Role Since
Amrit Nagpal Redmile Group Board Member 000 0000
Andrew McLean MD Oxford Sciences Innovation Board Member 000 0000
Antonin de Fougerolles Ph.D Evox Therapeutics Chief Executive Officer & Board Member 000 0000
Chau Khuong Self Board Member 000 0000
John McHutchison MD Self Board Member 000 0000
You’re viewing 5 of 14 board members. Get the full list »

Evox Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Evox Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
OrbiMed PE/Buyout Minority 000 0000 000000 0
The Invus Group PE/Buyout Minority 000 0000 000000 0
Duchenne UK Other 000 0000 000000 0
Innovate UK Government 000 0000 000000 0
Bill & Melinda Gates Foundation Not-For-Profit Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial